David Nicholas Gee Sells 2,198 Shares of Cellebrite DI (NASDAQ:CLBT) Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CMO David Nicholas Gee sold 2,198 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.24, for a total value of $24,705.52. Following the completion of the sale, the chief marketing officer owned 139,604 shares of the company’s stock, valued at $1,569,148.96. This trade represents a 1.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Nicholas Gee also recently made the following trade(s):

• On Monday, August 24th, David Nicholas Gee sold 4,323 shares of Cellebrite DI stock. The shares were sold at an average price of $11.36, for a total value of $49,109.28.
• On Wednesday, August 12th, David Nicholas Gee sold 230 shares of Cellebrite DI stock. The shares were sold at an average price of $16.07, for a total value of $3,696.10.

Cellebrite DI Stock Performance

CLBT opened at $11.29 on Wednesday. The company has a market capitalization of $2.82 billion, a PE ratio of 51.32, a P/E/G ratio of 1.59 and a beta of 1.18. The stock’s fifty day moving average is $14.21 and its 200-day moving average is $13.81. Cellebrite DI Ltd. has a one year low of $9.58 and a one year high of $19.98.

More Cellebrite DI News

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive: five analysts maintain Buy ratings, and the consensus price target is $16.70. Lake Street, DA Davidson, JPMorgan and Needham all retained positive ratings despite lowering their targets. Analyst ratings and price targets
• Positive Sentiment: Institutional ownership remains substantial at approximately 45.9%, with several funds—including Principal Financial, Renaissance Technologies and Roubaix Capital—reporting increased positions. This may provide some underlying support for the stock. Institutional ownership data
• Neutral Sentiment: The reported short-interest data shows zero shares sold short and a zero-day short-interest ratio. Because the figures imply no measurable short position and include an anomalous percentage change, they offer little useful signal for CLBT’s near-term direction.
• Negative Sentiment: Cellebrite’s chief marketing officer, David Nicholas Gee, sold an additional 4,323 shares worth about $49,100 on August 24, following a sale of 2,198 shares worth approximately $24,700 on August 21. The transactions reduced his holdings by 3.1% and 1.55%, respectively. The latest sale was conducted under a pre-arranged Rule 10b5-1 plan, which reduces—but does not eliminate—the bearish interpretation. CMO insider sale filing
• Negative Sentiment: The chief revenue officer, Marcus Jewell, sold 12,562 shares for approximately $141,200 on August 21. Multiple executive sales in a short period can pressure sentiment, particularly while the stock is well below its 52-week high. CRO insider sale filing
• Negative Sentiment: Kaplan Fox and Block & Leviton announced investigations into potential securities-law violations involving Cellebrite. The announcements do not establish wrongdoing, but they introduce legal and reputational risk and are likely contributing to selling pressure. Kaplan Fox investigation announcement

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on CLBT shares. DA Davidson cut their price target on shares of Cellebrite DI from $22.00 to $15.00 and set a “buy” rating for the company in a report on Friday, August 14th. Weiss Ratings downgraded shares of Cellebrite DI from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. reduced their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 14th. Finally, Lake Street Capital decreased their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CLBT. California State Teachers Retirement System raised its position in Cellebrite DI by 1,595.2% during the second quarter. California State Teachers Retirement System now owns 1,972,752 shares of the company’s stock valued at $28,802,000 after buying an additional 1,856,378 shares during the period. Wellington Management Group LLP boosted its position in Cellebrite DI by 93.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock worth $44,529,000 after acquiring an additional 1,475,579 shares during the period. Public Employees Retirement System of Ohio purchased a new position in Cellebrite DI during the 2nd quarter valued at about $454,000. Elevation Wealth Partners LLC purchased a new position in Cellebrite DI during the 2nd quarter valued at about $44,000. Finally, Moody National Bank Trust Division increased its holdings in shares of Cellebrite DI by 7.6% in the 2nd quarter. Moody National Bank Trust Division now owns 60,691 shares of the company’s stock valued at $886,000 after purchasing an additional 4,284 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.